Mara Ferrandi

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Selective SERCA2a activator as a candidate for chronic heart failure therapy.

Selective SERCA2a activator as a candidate for chronic heart failure therapy.

Journal: Journal of translational medicine

Published: November 14, 2023

Early consequences of the phospholamban mutation PLN-R14del+/- in a transgenic mouse model.

Early consequences of the phospholamban mutation PLN-R14del+/- in a transgenic mouse model.

Journal: Acta physiologica (Oxford, England)

Published: July 07, 2023

Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function.

Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function.

Journal: The Journal of pharmacology and experimental therapeutics

Published: May 30, 2022

Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure.

Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure.

Journal: Journal of medicinal chemistry

Published: May 17, 2022

Structural and Electrophysiological Changes in a Model of Cardiotoxicity Induced by Anthracycline Combined With Trastuzumab.

Structural and Electrophysiological Changes in a Model of Cardiotoxicity Induced by Anthracycline Combined With Trastuzumab.

Journal: Frontiers in physiology

Published: January 28, 2021

SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy.

SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy.

Journal: Cardiovascular research

Published: November 12, 2020

Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan.

Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan.

Journal: The pharmacogenomics journal

Published: June 29, 2020

Ouabain Contributes to Kidney Damage in a Rat Model of Renal Ischemia-Reperfusion Injury.

Ouabain Contributes to Kidney Damage in a Rat Model of Renal Ischemia-Reperfusion Injury.

Journal: International journal of molecular sciences

Published: May 31, 2016

Personalized Therapy of Hypertension: the Past and the Future.

Personalized Therapy of Hypertension: the Past and the Future.

Journal: Current hypertension reports

Published: February 26, 2016

SIK1 localizes with nephrin in glomerular podocytes and its polymorphism predicts kidney injury.

SIK1 localizes with nephrin in glomerular podocytes and its polymorphism predicts kidney injury.

Journal: Human molecular genetics

Published: November 14, 2014

Rostafuroxin protects from podocyte injury and proteinuria induced by adducin genetic variants and ouabain.

Rostafuroxin protects from podocyte injury and proteinuria induced by adducin genetic variants and ouabain.

Journal: The Journal of pharmacology and experimental therapeutics

Published: September 05, 2014

Quantitative proteomics reveals novel therapeutic and diagnostic markers in hypertension.

Quantitative proteomics reveals novel therapeutic and diagnostic markers in hypertension.

Journal: BBA clinical

Published: August 05, 2014

Showing 1-12 of 18

Last Updated: 09/26/2026